A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005%, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) With Plaque Psoriasis
Phase of Trial: Phase I
Latest Information Update: 17 May 2018
At a glance
- Drugs Calcipotriol (Primary)
- Indications Plaque psoriasis
- Focus Pharmacodynamics
- Sponsors Mayne Pharma
- 08 May 2018 Status changed from recruiting to completed.
- 15 May 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
- 15 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.